New corona drug for the first time in Japan Remdesibir Limited administration to severely ill patients May 8 4:00
The first new coronavirus treatment in Japan, "lemdecivir," was approved on the 7th. Since the distribution volume is limited and serious side effects may occur, it is planned to be administered only to critically ill patients.
Approved as a treatment for the new coronavirus is "lemdecibir" developed by the American pharmaceutical company "Gilliad Sciences".
"Lemdecivir" has been under development as a therapeutic drug for Ebola hemorrhagic fever, but it is expected to be effective for the treatment of new coronaviruses, and in the United States this month, urgent use was approved for critically ill patients. .
In Japan as well, a pharmaceutical company applied for it on the 4th of this month, and the Ministry of Health, Labor and Welfare has applied the “special approval” system, which greatly simplifies the examination process. Was approved as the first treatment in.
The subject of administration is limited to critically ill patients, as in the United States, and is said to be a person using an artificial heart-lung machine called "ECMO" or a respirator.
According to the Ministry of Health, Labor and Welfare, no out-of-pocket costs for patients are expected to occur.
On the other hand, there is a risk of serious kidney and liver damage as a side effect, so data will continue to be collected for all patients provided.
It is expected that 140,000 people will be supplied to the world for the time being, but the amount and time to be provided to Japan are yet to be decided. Due to the limited distribution volume, the government will administer it for the time being and prioritize provision to medical institutions that treat critically ill patients.